Cargando…

Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center

BACKGROUND: Regorafenib is an oral multikinase inhibitor and became the first second-line systemic treatment for hepatocellular carcinoma (HCC) following the phase III RESORCE trial. This single-center study retrospectively analyzed the clinical data and follow-up results of patients with recurrent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Qingwei, Rao, Wei, Huo, Junyu, Li, Zixiang, Wang, Song, Qiu, Wensheng, Guan, Ge, Xin, Yang, Fan, Ning, Cai, Jinzhen, Wu, Liqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890826/ https://www.ncbi.nlm.nih.gov/pubmed/36726082 http://dx.doi.org/10.1186/s12876-023-02661-2

Ejemplares similares

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2021)

Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma
por: Huo, Junyu, et al.
Publicado: (2022)

Integrated analysis of 1804 samples of six centers to construct and validate a robust immune-related prognostic signature associated with stromal cell abundance in tumor microenvironment for gastric cancer
por: Huo, Junyu, et al.
Publicado: (2022)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
por: Han, Yue, et al.
Publicado: (2021)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022)

Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Lee, Soon Kyu, et al.
Publicado: (2020)

Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
por: Hong, Young Mi, et al.
Publicado: (2021)

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
por: Glas, Martin, et al.
Publicado: (2019)

TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy
por: Song, Kangjian, et al.
Publicado: (2021)

Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma
por: Dai, Kunfu, et al.
Publicado: (2022)

On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2021)

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments
por: Reig, Maria, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma
por: He, Fu, et al.
Publicado: (2021)

Posttransplant sequential adrenal and spine metastasis of hepatocellular carcinoma responsive to combined regorafenib and radiotherapy: a case report
por: Kim, Jae-Yoon, et al.
Publicado: (2023)

Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice
por: Liu, Kan, et al.
Publicado: (2022)

Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation
por: Tsai, Tung-Hu, et al.
Publicado: (2021)

Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
por: Zhang, Er-lei, et al.
Publicado: (2020)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
por: Chiesa, Silvia, et al.
Publicado: (2022)

Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
por: Fasano, Morena, et al.
Publicado: (2023)

Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting
por: Hatori, Masahiro, et al.
Publicado: (2021)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Simultaneous and Sequential Use of Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Real-World Practice in China
por: Li, Jing, et al.
Publicado: (2023)

Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2021)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
por: Fung, Andrea S., et al.
Publicado: (2020)

Development and validation of a CTNNB1‐associated metabolic prognostic model for hepatocellular carcinoma
por: Huo, Junyu, et al.
Publicado: (2020)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib
por: Zhuo, Jianyong, et al.
Publicado: (2021)

Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study
por: Cao, Guang, et al.
Publicado: (2022)

A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2020)

Construction and Validation of a Reliable Six-Gene Prognostic Signature Based on the TP53 Alteration for Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2021)

Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2o0rfufp2r9ub34at48stsp9v8